[Therapy of hormone-refractory prostate cancer].

@article{Heidenreich2005TherapyOH,
  title={[Therapy of hormone-refractory prostate cancer].},
  author={Axel Heidenreich},
  journal={Der Urologe. Ausg. A},
  year={2005},
  volume={44 12},
  pages={1481-94; quiz 1495}
}
PSA-progression following primary ADT defines an androgen-refractory but still hormone sensitive PCA which might respond to secondary hormonal manipulations. Secondary hormonal manipulations will result in a PSA decline >50% in about 60-80% of the patients with a mean duration of 7-17 months depending on the type of treatment. PSA-progression following secondary endocrine treatment defines hormone-refractory prostate cancer (HRPCA) which might be treated by systemic chemotherapy. Based on the… CONTINUE READING